Compare BAFN & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | HOWL |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 30.7M |
| IPO Year | 2021 | 2021 |
| Metric | BAFN | HOWL |
|---|---|---|
| Price | $7.30 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 17.8K | ★ 321.6K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.80 | $0.53 |
| 52 Week High | $17.16 | $2.23 |
| Indicator | BAFN | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 66.06 | 53.38 |
| Support Level | $6.31 | $0.79 |
| Resistance Level | $8.26 | $0.90 |
| Average True Range (ATR) | 0.49 | 0.10 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 93.90 | 33.88 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.